The RABBIT-2 trial showed that a basal-bolus insulin regimen improved glycemic control compared to sliding-scale insulin (SSI) in non-critical patients with type 2 diabetes, achieving mean glucose levels of 166 versus 193 mg/dL [1]. This evidence concerns the gene INS and type 2 diabetes mellitus.